Gosset Ownership
Private
Employees
~3
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Neuralstem General Information
Neuralstem developed a proprietary platform to generate human regionally specific neural stem cells and neurogenic small molecules. Its lead programs were: NSI‑566—an allogeneic human spinal cord-derived neural stem cell line—advanced through early clinical trials for ALS, chronic spinal cord injury, and paralysis from stroke. The company also developed the small molecule compound NSI‑189 for major depressive disorder. Both platforms reached at least Phase II clinical development. As of the last available updates (~2019), no new major clinical progress has been reported publicly.
Contact Information
Primary Industry
Biotech
Corporate Office
Germantown, Maryland
United States
United States
Drug Pipeline
NSI-189
Phase 2Key Partnerships
Tianjin Pharmaceutical Group International Holdings Co., LTD.—strategic investment ($20 million in Dec. 2016)
Neuralstem Funding
No funding data available
To view Neuralstem's complete valuation and funding history, request access »